Impact of lack of suppression of glucagon on glucose tolerance in humans.

People with type 2 diabetes have defects in both α- and β-cell function. To determine whether lack of suppression of glucagon causes hyperglycemia when insulin secretion is impaired but not when insulin secretion is intact, twenty nondiabetic subjects were studied on two occasions. On both occasions, a "prandial" glucose infusion was given over 5 h while endogenous hormone secretion was inhibited. Insulin was infused so as to mimic either a nondiabetic ( n = 10) or diabetic ( n = 10) postprandial profile. Glucagon was infused at a rate of 1.25 ng ⋅ kg-1 ⋅ min-1, beginning either at time zero to prevent a fall in glucagon (nonsuppressed study day) or at 2 h to create a transient fall in glucagon (suppressed study day). During the "diabetic" insulin profile, lack of glucagon suppression resulted in a marked increase ( P < 0.002) in both the peak glucose concentration (11.9 ± 0.4 vs. 8.9 ± 0.4 mmol/l) and the area above basal of glucose (927 ± 77 vs. 546 ± 112 mmol ⋅ l-1 ⋅ 6 h) because of impaired ( P < 0.001) suppression of glucose production. In contrast, during the "nondiabetic" insulin profile, lack of suppression of glucagon resulted in only a slight increase ( P< 0.02) in the peak glucose concentration (9.1 ± 0.4 vs. 8.4 ± 0.3 mmol/l) and the area above basal of glucose (654 ± 146 vs. 488 ± 118 mmol ⋅ l-1 ⋅ 6 h). Of interest, when glucagon was suppressed, glucose concentrations differed only minimally during the nondiabetic and diabetic insulin profiles. These data indicate that lack of suppression of glucagon can cause substantial hyperglycemia when insulin availability is limited, therefore implying that inhibitors of glucagon secretion and/or glucagon action are likely to be useful therapeutic agents in such individuals.

[1]  C Meyer,et al.  Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. , 1998, Metabolism: clinical and experimental.

[2]  L. Audoly,et al.  Regulation of glucose production by NEFA and gluconeogenic precursors during chronic glucagon infusion. , 1998, American journal of physiology. Endocrinology and metabolism.

[3]  M. Vranic,et al.  Role of free fatty acids and glucagon in the peripheral effect of insulin on glucose production in humans. , 1998, The American journal of physiology.

[4]  M. Camilleri,et al.  Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans. , 1998, Metabolism: clinical and experimental.

[5]  R. Rizza,et al.  Assessment of Hepatic Sensitivity to Glucagon in NIDDM: Use as a Tool to Estimate the Contribution of the Indirect Pathway to Nocturnal Glycogen Synthesis , 1997, Diabetes.

[6]  C Cobelli,et al.  Impaired Basal Glucose Effectiveness in NIDDM: Contribution of Defects in Glucose Disappearance and Production, Measured Using an Optimized Minimal Model Independent Protocol , 1997, Diabetes.

[7]  V. Hruby,et al.  Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. , 1996, Endocrinology.

[8]  J. Holst,et al.  Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.

[9]  C. Cobelli,et al.  Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. , 1996, The Journal of clinical investigation.

[10]  J. Holst,et al.  The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones , 1996, Diabetes.

[11]  R. B. Merrifield,et al.  Antibodies against specific extracellular epitopes of the glucagon receptor block glucagon binding. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Wahren,et al.  A limitation in the use of mass isotopomer distributions to measure gluconeogenesis in fasting humans. , 1995, The American journal of physiology.

[13]  D L Rothman,et al.  Contribution of Hepatic Glycogenolysis to Glucose Production in Humans in Response to a Physiological Increase in Plasma Glucagon Concentration , 1995, Diabetes.

[14]  R. Bergman,et al.  Quantitation of measurement error with Optimal Segments: basis for adaptive time course smoothing. , 1993, The American journal of physiology.

[15]  S. Mathewes,et al.  Isolation of glucagon antagonists by random molecular mutagenesis and screening. , 1993, Molecular pharmacology.

[16]  C. Cobelli,et al.  Methods for assessment of the rate of onset and offset of insulin action during nonsteady state in humans. , 1993, The American journal of physiology.

[17]  S. Post,et al.  Mechanism of action of des-His1-[Glu9]glucagon amide, a peptide antagonist of the glucagon receptor system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Jensen,et al.  Effects of glucagon on free fatty acid metabolism in humans. , 1991, The Journal of clinical endocrinology and metabolism.

[19]  R. Rizza,et al.  Contribution to Postprandial Hyperglycemia and Effect on Initial Splanchnic Glucose Clearance of Hepatic Glucose Cycling in Glucose-Intolerant or NIDDM Patients , 1991, Diabetes.

[20]  A. Cherrington,et al.  Effects of insulin on glucagon-stimulated glucose production in the conscious dog. , 1990, Metabolism: clinical and experimental.

[21]  T. Jenssen,et al.  Contribution of Abnormal Muscle and Liver Glucose Metabolism to Postprandial Hyperglycemia in NIDDM , 1990, Diabetes.

[22]  T. Jenssen,et al.  Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. , 1990, Diabetes.

[23]  R. Rizza,et al.  Effects of Basal Insulin Supplementation on Disposition of Mixed Meal in Obese Patients With NIDDM , 1989, Diabetes.

[24]  Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27. , 1989, The Journal of biological chemistry.

[25]  R. Hartung Dose—Response Relationships , 1987 .

[26]  R. Rizza,et al.  Assessment of insulin action in insulin-dependent diabetes mellitus using [6(14)C]glucose, [3(3)H]glucose, and [2(3)H]glucose. Differences in the apparent pattern of insulin resistance depending on the isotope used. , 1986, The Journal of clinical investigation.

[27]  M. Vranic,et al.  Minimal Increases in Glucagon Levels Enhance Glucose Production in Man with Partial Hypoinsulinemia , 1983, Diabetes.

[28]  P. Cryer,et al.  Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. , 1983, The Journal of clinical investigation.

[29]  R. DeFronzo,et al.  Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. , 1982, The American journal of physiology.

[30]  G. Shulman,et al.  Differential Time Course of Glucagon's Effect on Glycogenolysis and Gluconeogenesis in the Conscious Dog , 1981, Diabetes.

[31]  R. Sherwin,et al.  Evidence for an important role of changes in rather than absolute concentrations of glucagon in the regulation of glucose production in humans. , 1980, The Journal of clinical endocrinology and metabolism.

[32]  J. Liljenquist,et al.  Lack of a role for glucagon in the disposal of an oral glucose load in normal man. , 1979, The Journal of clinical endocrinology and metabolism.

[33]  P. Raskin,et al.  Effects of insulin on the response of immunoreactive glucagon to an intravenous glucose load in human diabetes. , 1979, Metabolism: Clinical and Experimental.

[34]  R. Rizza,et al.  Persistent effect of sustained hyperglucagonemia on glucose production in man. , 1979, The Journal of clinical endocrinology and metabolism.

[35]  R. Sherwin,et al.  Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. , 1976, The New England journal of medicine.

[36]  R. Steele,et al.  Measurement of size and turnover rate of body glucose pool by the isotope dilution method. , 1956, The American journal of physiology.